Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2002
10/31/2002US20020160984 For example, 2,3-dihydro-1H-benz(de)isoquinolin-1-one; treating diabetes, cancer, radiosensitizing tumor cells, cardiovascular disorders, septic shock, inflammatory bowel disease, senescent cells
10/31/2002US20020160983 Substituted benzopyranones as telomerase inhibitors
10/31/2002US20020160980 Method of treating hepatitis delta virus infection
10/31/2002US20020160978 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
10/31/2002US20020160965 Cosmetic and dermatological formulations comprising flavonoids
10/31/2002US20020160962 Non-structural protein 3 (NS3), part of a hepatitis C virus protease necessary for polypeptide processing and viral replication; alpha-ketoamide compounds of given formula
10/31/2002US20020160961 Thyrotropin-Releasing Hormone (TRH) and a peptide of given formula, such as ipamorelin; treatment of wasting
10/31/2002US20020160957 Treating tumors
10/31/2002US20020160948 Such as preventing or treating primary cancer cell growth
10/31/2002US20020160933 Methods and compositions for producing a neurosalutary effect in a subject
10/31/2002US20020160499 For use in diagnosis, prophylaxis, and therapy of disorders associated with expression of serine carboxypeptidase
10/31/2002US20020160494 Tendon-inducing compositions
10/31/2002US20020160493 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies
10/31/2002US20020160487 Testis specific transcription factor ZGCL-1
10/31/2002US20020160484 Central nervous system disorders therapy; genetic engineering
10/31/2002US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002US20020160477 CAF1-related protein
10/31/2002US20020160438 Modulate kinase; antiinflammatory agents; respiratory system disorders
10/31/2002US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects
10/31/2002US20020160383 Use of nucleic acid analogues in diagnostics and analytical procedures
10/31/2002US20020160379 Gapped 2' modified oligonucleotides
10/31/2002US20020160109 Microencapsulation of drugs by solvent exchange
10/31/2002US20020160061 Use of legume products for the treatment of external aggressions
10/31/2002US20020160058 Antialopecia agent
10/31/2002US20020160053 Solution for promoting growth of tissue cells at wound sites and production process therefor
10/31/2002US20020160027 Conjugate, its preparation and use
10/31/2002US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002US20020159968 A stable polyallylamine hydrochloride polymer crosslinked by epichlorohydrin
10/31/2002US20020159956 Providing a chewing gum, includes a gum center and a coating coverings, coating includes a drug designed to be delivered into systemic system of indivisual
10/31/2002US20020158255 Compounds of the general formula P1-L-P2; wherein "P1" is a pyrazinoylguanidine sodium channel blocker, "L" is a linking group, and "P2" is either (i) a pyrazinoylguanidine sodium channel blocker or (ii) a P2Y2 receptor agonist, are disclosed
10/31/2002DE10121217A1 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden 6H-oxazolo [4,5-e] indole derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands
10/31/2002DE10121215A1 Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden Dihydro-imidazo [4,5-e] indole and 7H-pyrrolo [3,2-f] quinoxaline derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands
10/31/2002DE10121113A1 Genmodifizierte YT Zelllinie und ihre Verwendung Genetically Modified YT cell line and their use
10/31/2002DE10120627A1 Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren Use of Phyllanthus for the treatment or prophylaxis of infections caused by hepatitis B viruses
10/31/2002DE10118452A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid
10/31/2002CA2445740A1 Use of metals to treat inflammatory skin conditions
10/31/2002CA2445734A1 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002CA2445729A1 Use of metals to treat mucosal membranes
10/31/2002CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002CA2445168A1 Human timp-1 antibodies
10/31/2002CA2445071A1 Oligonucleotide compositions and their use to induce differentiation of cells
10/31/2002CA2444885A1 Methods and compositions for treating oral and esophageal lesions
10/31/2002CA2444691A1 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
10/31/2002CA2444675A1 Secreted proteins
10/31/2002CA2444595A1 Benzimidazolone derivatives
10/31/2002CA2444570A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors
10/31/2002CA2444563A1 Tissue fibrosis inhibitors
10/31/2002CA2444381A1 Novel compounds
10/31/2002CA2444370A1 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002CA2444219A1 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002CA2444214A1 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
10/31/2002CA2444095A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/31/2002CA2444036A1 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/31/2002CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002CA2443587A1 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002CA2442994A1 Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
10/31/2002CA2442591A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
10/31/2002CA2442112A1 Use of creatine for the amelioration of oxidative stress
10/31/2002CA2439690A1 Modified interferon alpha with reduced immunogenicity
10/31/2002CA2436273A1 Method for producing an active ingredient concentrate, and an active ingredient concentrate
10/31/2002CA2429351A1 A novel human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
10/30/2002EP1253142A1 Compounds exhibiting thrombopoietin receptor agonism
10/30/2002EP1252888A1 Biologically active labdane or labdene derivatives from Cistus
10/30/2002EP1252882A1 Process to increase the threshold tolerance of the sensitive skin
10/30/2002EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002EP1252330A2 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
10/30/2002EP1252323A2 Virus strains for the oncolytic treatment of cancer
10/30/2002EP1252322A2 Herpes virus strains for gene therapy
10/30/2002EP1252310A2 Mlp gene, nucleic acids, polypeptides and the utilization thereof
10/30/2002EP1252300A2 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
10/30/2002EP1252189A2 Novel human nucleic acid molecules and polypeptides encoding cation channels
10/30/2002EP1252178A1 Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
10/30/2002EP1252177A1 Ligand for vascular endothelial growth factor receptor
10/30/2002EP1252175A1 Antisense modulation of survivin expression
10/30/2002EP1252171A1 Method for preparing functionalised beta-(1,3)-glucan derivatives
10/30/2002EP1252164A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid
10/30/2002EP1252163A2 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
10/30/2002EP1252161A1 Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor
10/30/2002EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002EP1252155A1 Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
10/30/2002EP1252154A1 Heterocyclic amide derivatives
10/30/2002EP1252153A1 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
10/30/2002EP1252152A1 Urea compounds as inhibitors for vla-4
10/30/2002EP1252150A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
10/30/2002EP1252146A1 Amide compounds for inhibiting protein kinases
10/30/2002EP1252145A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/30/2002EP1252144A1 Substituted glutarimides and use thereof il-12 production inhibitors
10/30/2002EP1252143A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives
10/30/2002EP1252142A1 Indole derivatives as mcp-1 receptor antagonists
10/30/2002EP1252141A1 Tosylproline analogs as thymidylate synthase inhibitors
10/30/2002EP1252138A2 A new process for the preparation of latanoprost
10/30/2002EP1252133A2 Pharmaceutical compounds
10/30/2002EP1251868A1 Combination therapy for the treatment of inflammatory and respiratory diseases
10/30/2002EP1251865A1 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
10/30/2002EP1251864A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
10/30/2002EP1251861A2 Physiologically active compositions of basidiomycotina and araliaceae extracts
1 ... 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 ... 1564